The contribution of rare variants to risk of 1 schizophrenia in individuals with and without 2 intellectual disability

By performing a meta-analysis of rare coding variants in whole-exome sequences from 4,133 schizophrenia cases and 9,274 controls, de novo mutations in 1,077 family trios, and copy number variants from 6,882 cases and 11,255 controls, we show that individuals with schizophrenia carry a significant burden of rare, damaging variants in 3,488 genes previously identified as having a near-complete depletion of loss-of-function variants. In patients with schizophrenia who also have intellectual disability, this burden is concentrated in risk genes associated with neurodevelopmental disorders. After excluding known risk genes for neurodevelopmental disorders, a significant rare variant burden persists in other genes intolerant of loss-of-function variants; although this effect is notably stronger in patients with both schizophrenia and intellectual disability, it is also seen in patients with schizophrenia who do not have intellectual disability. Together, our results show that rare, damaging variants contribute to the risk of schizophrenia both with and without intellectual disability and support an overlap of genetic risk between schizophrenia and other neurodevelopmental disorders.

[1]  S. Levy,et al.  Exome sequencing supports a de novo mutational paradigm for schizophrenia , 2011, Nature Genetics.

[2]  Michael Q. Zhang,et al.  HITS-CLIP and integrative modeling define the Rbfox splicing-regulatory network linked to brain development and autism. , 2014, Cell reports.

[3]  Tomas W. Fitzgerald,et al.  Large-scale discovery of novel genetic causes of developmental disorders , 2014, Nature.

[4]  D. Rujescu,et al.  Exome Sequencing in 53 Sporadic Cases of Schizophrenia Identifies 18 Putative Candidate Genes , 2014, PloS one.

[5]  Jianxin Shi,et al.  Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs , 2013, Nature Genetics.

[6]  Patrick F. Sullivan,et al.  CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1 , 2013, Human molecular genetics.

[7]  S. Lok,et al.  Increased exonic de novo mutation rate in individuals with schizophrenia , 2011, Nature Genetics.

[8]  Joshua M. Korn,et al.  Accurately Assessing the Risk of Schizophrenia Conferred by Rare Copy-Number Variation Affecting Genes with Brain Function , 2010, PLoS genetics.

[9]  Stephan J Sanders,et al.  The autism-associated chromatin modifier CHD8 regulates other autism risk genes during human neurodevelopment , 2015, Nature Communications.

[10]  Exome sequencing identifies rare LDLR and APOA 5 alleles conferring risk for myocardial infarction , 2016 .

[11]  E. Banks,et al.  De novo mutations in schizophrenia implicate synaptic networks , 2014, Nature.

[12]  Jakob Grove,et al.  Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection , 2018, Nature Genetics.

[13]  Stephan Heckers,et al.  Definition and description of schizophrenia in the DSM-5 , 2013, Schizophrenia Research.

[14]  C. Spencer,et al.  A contribution of novel CNVs to schizophrenia from a genome-wide study of 41,321 subjects: CNV Analysis Group and the Schizophrenia Working Group of the Psychiatric Genomics Consortium , 2016, bioRxiv.

[15]  Boris Yamrom,et al.  The contribution of de novo coding mutations to autism spectrum disorder , 2014, Nature.

[16]  Uwe Ohler,et al.  FMR1 targets distinct mRNA sequence elements to regulate protein expression , 2012, Nature.

[17]  N. Wray,et al.  Contrasting genetic architectures of schizophrenia and other complex diseases using fast variance components analysis , 2015, Nature Genetics.

[18]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[19]  Laura J. Scott,et al.  Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways , 2015, Nature Neuroscience.

[20]  Giulio Genovese,et al.  Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia , 2016, Nature Neuroscience.

[21]  Stephan J Sanders,et al.  A framework for the interpretation of de novo mutation in human disease , 2014, Nature Genetics.

[22]  Patrick F. Sullivan,et al.  Ultra-rare disruptive and damaging mutations influence educational attainment in the general population , 2016, Nature Neuroscience.

[23]  Joan,et al.  Prevalence and architecture of de novo mutations in developmental disorders , 2017, Nature.

[24]  I. Ionita-Laza,et al.  Loss-of-Function Variants in Schizophrenia Risk and SETD1A as a Candidate Susceptibility Gene , 2014, Neuron.

[25]  Christopher S. Poultney,et al.  Synaptic, transcriptional, and chromatin genes disrupted in autism , 2014, Nature.

[26]  Manuel Corpas,et al.  DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. , 2009, American journal of human genetics.

[27]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[28]  Deciphering Developmental Disorders Study,et al.  Prevalence and architecture of de novo mutations in developmental disorders , 2017, Nature.

[29]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[30]  M C O'Donovan,et al.  Copy number variation in schizophrenia in Sweden , 2014, Molecular Psychiatry.

[31]  David M. Herrington,et al.  Multiple rare alleles at LDLR and APOA5 confer risk for early-onset myocardial infarction , 2014, Nature.

[32]  S Purcell,et al.  De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia , 2011, Molecular Psychiatry.

[33]  D. Licatalosi,et al.  FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism , 2011, Cell.

[34]  G. Kirov,et al.  The Penetrance of Copy Number Variations for Schizophrenia and Developmental Delay , 2014, Biological Psychiatry.

[35]  Giulio Genovese,et al.  Schizophrenia risk from complex variation of complement component 4 , 2016, Nature.

[36]  Jakob Grove,et al.  Genetic risk for autism spectrum disorders and neuropsychiatric variation in the general population , 2015, Nature Genetics.

[37]  G. Kirov,et al.  Analysis of copy number variations at 15 schizophrenia-associated loci , 2014, The British journal of psychiatry : the journal of mental science.

[38]  G. Kirov,et al.  CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1 , 2013, Human molecular genetics.

[39]  P. Visscher,et al.  Rare chromosomal deletions and duplications increase risk of schizophrenia , 2008, Nature.

[40]  N. Franck,et al.  [Neurodevelopmental hypothesis of schizophrenia]. , 2002, La Revue du praticien.

[41]  J N Giedd,et al.  Neurodevelopmental model of schizophrenia: update 2012 , 2012, Molecular Psychiatry.

[42]  E. Johnstone,et al.  ‘Pfropfschizophrenie’ revisited , 1998, British Journal of Psychiatry.

[43]  Shamil R Sunyaev,et al.  Pooled association tests for rare variants in exon-resequencing studies. , 2010, American journal of human genetics.

[44]  G. Arbanas.  Diagnostic and Statistical Manual of Mental Disorders (DSM-5) , 2015 .

[45]  Seungtai Yoon,et al.  De novo Mutations in Schizophrenia Implicate Chromatin Remodeling and Support a Genetic Overlap with Autism and Intellectual Disability , 2014, Molecular Psychiatry.

[46]  Minna Männikkö,et al.  Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders , 2016, Nature Neuroscience.

[47]  Christopher S. Poultney,et al.  Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci , 2015, Neuron.

[48]  Eric S. Lander,et al.  A polygenic burden of rare disruptive mutations in schizophrenia , 2014, Nature.

[49]  A. Need,et al.  One gene, many neuropsychiatric disorders: lessons from Mendelian diseases , 2014, Nature Neuroscience.

[50]  Michael J Owen,et al.  New Approaches to Psychiatric Diagnostic Classification , 2014, Neuron.

[51]  G. Kirov,et al.  Novel Findings from CNVs Implicate Inhibitory and Excitatory Signaling Complexes in Schizophrenia , 2015, Neuron.

[52]  S. Levy,et al.  De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia , 2012, Nature Genetics.

[53]  Abraham Weizman,et al.  Genotype-phenotype correlation in 22q11.2 deletion syndrome , 2012, BMC Medical Genetics.

[54]  Naomi R. Wray,et al.  Common schizophrenia alleles are enriched in mutation-intolerant genes and maintained by background selection , 2016, bioRxiv.

[55]  Jonathan Berg,et al.  22q11.2 distal deletion: a recurrent genomic disorder distinct from DiGeorge syndrome and velocardiofacial syndrome. , 2008, American journal of human genetics.

[56]  S. Kapur,et al.  The dopamine hypothesis of schizophrenia: version III--the final common pathway. , 2009, Schizophrenia bulletin.